Results 91 to 100 of about 8,545 (210)
COVID‐19 Prophylactic Effect of Bromhexine Hydrochloride
Immunity, Inflammation and Disease, Volume 14, Issue 4, April 2026.ABSTRACT Introduction Despite extensive efforts to identify effective treatments for COVID‐19, preventive strategies remain essential. Bromhexine hydrochloride (BRH), an over‐the‐counter mucolytic with potential TMPRSS2 inhibition, may reduce viral entry and thus serve as a prophylactic agent.
Vanyo Mitev +4 more
wiley +1 more source
Clinical and Translational Science, 2022 The ongoing pandemic of severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) and subsequently, coronavirus disease 2019 (COVID‐19), has led to the deaths of over 6.1 million people and sparked a greater interest in virology to expedite the ...
Raymond K. Hau +2 more
doaj +1 more source
Crystalline form of Molnupiravir and process for its preparation thereof [PDF]
, 2021 Crystalline form of ((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate ...
core +1 more source
Microbial Biotechnology, Volume 19, Issue 4, April 2026.The target sites of COVID‐19 antivirals discussed in the present opinion paper, namely the RNA dependent RNA polymerase Nsp12 and of the main viral protease Nsp5, are indicated by a red star in the overview of the replication cycle of coronavirus SARS‐CoV‐2.
Harald Brüssow
wiley +1 more source
Health Science Reports, Volume 9, Issue 3, March 2026.ABSTRACT Background and Aims This study aimed to compare the clinical symptoms of mild COVID‐19 and influenza during a period when both diseases circulated in the 2023–2024 influenza season in Japan. Methods Outpatients diagnosed with COVID‐19, influenza A, or influenza B by antigen test kits at 10 medical facilities in Japan were enrolled.
Takuma Bando +10 more
wiley +1 more source
A Systematic Review of Nirmatrelvir/Ritonavir and Molnupiravir for the Treatment of Coronavirus Disease 2019 [PDF]
BackgroundTo address the need for treatments for patients with coronavirus disease 2019 (COVID-19), 3 therapies have been given either full approval or Emergency Use Authorization.
Haslam, Alyson, Prasad, Vinay
core +1 more source
New Zealand Journal of Botany, Volume 64, Issue 1, March 2026.SARS‐CoV2 Omicron and its substrains are still a critical global health issue and extremely contagious, even with widespread vaccination efforts. Hospitalizations and mortality rates linked to these variants are still prevalent. Current therapeutic options face challenges, including low effectiveness, suboptimal pharmacokinetics, and drug resistance ...
Frank Eric Tatsing Foka +1 more
wiley +1 more source
Reviews in Medical Virology, Volume 36, Issue 2, March 2026.ABSTRACT Small randomized controlled trials (RCTs) in COVID‐19 meta‐analyses have been associated with more favourable treatment effects and reduced result stability. This study assessed how trial size impacts effect estimates, statistical stability, and risk of bias.
Dong Hyun Kim +11 more
wiley +1 more source
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens
iScienceSummary: Direct acting antivirals (DAAs) represent critical tools for combating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that have escaped vaccine-elicited spike-based immunity and future coronaviruses with ...
Irfan Ullah +13 more
doaj +1 more source
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment:a retrospective cohort study [PDF]
BACKGROUND: The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating variants remains unclear. We sought to describe characteristics and clinical outcomes of highest risk patients with COVID-19 receiving early COVID ...
Birch, Helen J +8 more
core +3 more sources